Bluhm Cardiovascular Institute, Center for Artificial Intelligence, Northwestern Medicine, Chicago, Illinois, USA; Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.
McGaw Medical Center, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.
J Am Coll Cardiol. 2024 Jun 25;83(25):2674-2689. doi: 10.1016/j.jacc.2024.03.431.
Iron deficiency and heart failure frequently co-occur, sparking clinical research into the role of iron repletion in this condition over the last 20 years. Although early nonrandomized studies and subsequent moderate-sized randomized controlled trials showed an improvement in symptoms and functional metrics with the use of intravenous iron, 3 recent larger trials powered to detect a difference in hard cardiovascular outcomes failed to meet their primary endpoints. Additionally, there are potential concerns related to side effects from intravenous iron, both in the short and long term. This review discusses the basics of iron biology and regulation, the diagnostic criteria for iron deficiency and the clinical evidence for intravenous iron in heart failure, safety concerns, and alternative therapies. We also make practical suggestions for the management of patients with iron deficiency and heart failure and outline key areas in need of future research.
缺铁和心力衰竭经常同时发生,这促使临床研究在过去 20 年中探讨了铁补充在这种情况下的作用。尽管早期的非随机研究和随后的中等规模随机对照试验显示,使用静脉铁可以改善症状和功能指标,但最近 3 项旨在检测心血管硬终点差异的大型试验未能达到主要终点。此外,静脉铁在短期和长期都可能存在副作用方面的担忧。这篇综述讨论了铁生物学和调节的基础知识、缺铁的诊断标准以及心力衰竭中静脉铁的临床证据、安全性问题和替代疗法。我们还为缺铁和心力衰竭患者的管理提出了实用建议,并概述了未来研究的重点领域。